Dale Renlund

Dale G. Renlund, M.D.

Current Titles:
Professor of Internal Medicine (Cardiology), University of Utah School of Medicine
Medical Director, UTAH Cardiac Transplant Program
Director, Heart Failure Prevention & Treatment Program, Intermountain Medical Center

Clinical Interests:
Immunosuppression
Heart failure medical therapies

Research Interests:
Immunosuppression
Outcomes in heart failure populations
Cardiac resynchronization therapies

Society Memberships:
International Society for Heart and Lung Transplantation
Transplantation Society
American Heart Association
American College of Cardiology
Heart Failure Society of America

Pertinent Publications:
1. Renlund DG, Gerstenblith G, Lakatta EG, Jacobus WE, Kallman CH, Weisfeldt ML. Perfusate sodium during ischemia modifies post ischemic functional and metabolic recovery in the rabbit heart. J Mol Cell Cardiol 16:795-801, 1984

2. Renlund DG, Lakatta EG, Mellits ED, Gerstenblith G. Calcium dependent enhancement of myocardial diastolic tone and energy utilization dissociates systolic work and oxygen consumption during low sodium perfusion. Circulation Research 57:876-888, 1985

3. Hoerter JA, Miceli MV, Renlund DG, Jacobus WE, Gerstenblith G, Lakatta EG. A 31-P NMR study of the metabolic, contractile and ionic consequences of induced Ca 2+ alterations in the isovolumic rat heart. Circulation Research 58:539-551, 1986

4. Plotnick GD, Becker LC, Fisher ML, Gerstenblith G, Renlund DG, Fleg JL, Lakatta EG. Use of the Frank-Starling mechanism in submaximal versus maximal upright exercise. Am J Physiol 20:H1101-1105, 1986

5. Renlund DG, Hanley D, Traill TA. Guillain-Barre' Syndrome following coronary artery bypass surgery. Am Heart Journal 113:844-845, 1987

6. Gilbert EM, Dewitt CW, Eiswirth CC, Renlund DG, Menlove RL, Freedman LA, Herrick CM, Gay WA, Bristow MR. Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. Am J Med 82:202-206, 1987

7. Gilbert EM, Eiswirth CC, Renlund DG, Menlove RL, DeWitt CW, Freedman LA, Herrick CM, Gay WA, Bristow MR. Use of OKT3 monoclonal antibody in cardiac transplantation: Early experience with rejection prophylaxis and treatment of refractory rejection. Transplant Proceedings 19(Supplement 1):45-53, 1987

8. Renlund DG, Bristow MR, Burton NA, Jones KW, Karwande SV, Gay WA Jr. U.T.A.H. Cardiac Transplant Program: Survival following cardiac transplantation: What are acceptable standards? Western J Med 146:627-630, 1987

9. Renlund DG, O'Connell JB, Gilbert EM, Watson FS, Bristow MR. Feasibility of discontinuation of corticosteroid maintenance in cardiac transplantation. J Heart Transplantation 6:71-78, 1987

10. Renlund DG, Gilbert EM, O'Connell JB, Gay WA Jr, Jones KW, Burton NA, Doty DB, Karwande SV, DeWitt CW, Menlove RL, Herrick CM, Bristow MR. Age-associated decline in cardiac allograft rejection. Am J Med 83:391-398, 1987

11. Renlund DG, Chandra NC, Gottlieb SO. Multiple coronary thromboses in previously normal coronary arteries treated with streptokinase. Catheterization and Cardiovascular Diagnosis 13:327-330, 1987

12. Renlund DG, Lakatta EG, Fleg JL, Becker LC, Clulow JF, Weisfeldt ML, Gerstenblith G. Prolonged decrease in cardiac volumes following maximal upright bicycle exercise. J Applied Physiology 63:1947-1955, 1987

13. Gilbert EM, Renlund DG, O'Connell JB, Eiswirth CC, Gay WA, Bristow MR. Immunosuppressive efficacy of vincristine in heart transplantation: A preliminary report. J Heart Transplantation 6:369-374, 1987

14. Watson FS, O'Connell JB, Amber IJ, Renlund DG, Classen D, Johnston JM, Smith CB, Bristow MR. Treatment of cytomegalovirus pneumonia in heart transplant recipients with 9(1,3-dihydroxy-2-proproxymethyl)- guanine (DHPG). J Heart Transplant 7:102-105, 1988

15. Wittwer CT, Bristow MR, Gilbert EM, Renlund DG, O'Connell JB, DeWitt CW. OKT3 therapy as a cause of high panel reactive antibodies in serum using standard microcytotoxicity techniques. Transplantation 45:832-834, 1988

16. Yowell RL, Hammond EH, Bristow MR, Watson FS, Renlund DG, O'Connell JB. Acute vascular rejection involving the major coronary arteries of a cardiac allograft. J Heart Transplant 7:191-197, 1988

17. Gilbert EM, Krueger SK, Murray JL, Renlund DG, O'Connell JB, Gay WA, Bristow MR. Echocardiographic evaluation of potential cardiac transplant donors. J Thorac Cardiovasc Surg 95:1003-1007 1988

18. Bristow MR, Gilbert EM, Renlund DG, DeWitt CW, Burton NA, O'Connell JB. Use of OKT3 monoclonal antibody in cardiac transplantation: Review of the initial experience. J Heart Transplantation 7:1-11, 1988

19. Bristow MR, Renlund DG, Gilbert EM, Lee HR, Gay WA Jr, O'Connell JB. Murine monoclonal CD-3 antibody in cardiac transplantation: Anti-rejection treatment and retreatment and preliminary results in a prospectively randomized trial for prophylaxis. Clinical Transplantation 2:163-168, 1988

20. Gay WA Jr, O'Connell JB, Burton NA, Karwande SV, Renlund DG, Bristow MR. OKT3 monoclonal antibody in cardiac transplantation: Experience with 102 patients. Annals of Surgery 208:287-290, 1988

21. O'Connell JB, Renlund DG, Robinson JA, Fowler MB, Oyer PE, Pifarre R, Grady KL, Mullin AV, Menlove RL, Gay WA Jr, Bristow MR. Effect of preoperative hemodynamic support on survival following cardiac transplantation. Circulation 78 (Supplement III):III-78-III-82, 1988

22. Becker DM, Chamberlain B, Pearson TA, Swank R, Girardet R, Baughman KL, Kwiterovich PO, Hegewald MG, Renlund DG. Cumulative corticosteroid exposure and serum lipids in heart transplant recipients. Am J Medicine 85:632-638, 1988

23. Crandall BG, Renlund DG, O'Connell JB, Burton NA, Jones KW, Gay WA Jr, Doty DB, Karwande SV, Lee HR, Holland C, Menlove RL, Hammond ME, Bristow MR. Increased cardiac allograft rejection in female cardiac transplant recipients. J Heart Transplant 7:419-423, 1988

24. Bristow MR, Lee HE, Gilbert EM Renlund DG, Hegewald MG, Hershberger RE, O'Connell JB. Use of enoximone in patients awaiting cardiac transplant. British Journal of Clinical Practice 48(Supplement 64):69-72, 1988

25. Renlund DG, O'Connell JB, Gilbert EM, Hammond ME, Burton NA, Jones KW, Karwande SV, Doty DB, Menlove RL, Herrick CM, Lee HR, Gay WA Jr, Bristow MR. A prospective comparison of murine monoclonal CD-3 antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation: Decreased rejection and less corticosteroid use with OKT3. Transplantation 47:599-605, 1989

26. O'Connell JB, Renlund DG, Gay WA, DeWitt CW, Hammond EH, Yowell RL, Jones KW, Karwande SV, Doty DB, Bristow MR. Efficacy of OKT3 retreatment for refractory cardiac allograft rejection. Transplantation 47:788-792, 1989

27. Renlund DG, Bristow MR, Crandall BG, Burton NA, Doty DB, Karwande SV, Gay WA Jr, Jones KW, Hegewald MG, Hagan ME, Lee HR, O'Connell JB. Hypercholesterolemia after cardiac transplantation: Amelioration by corticosteroid-free maintenance immunosuppression. J Heart Transplant 8:214-220, 1989

28. Hegewald MG, O'Connell JB, Renlund DG, Lee HR, Burton NA, Karwande SV, Jones KW, Lassetter JE, Bristow MR. OKT3 monoclonal antibody given for ten versus fourteen days as immunosuppressive prophylaxis in heart transplantation. J Heart Transplant 8:303-310, 1989

29. Merrell SW, Ames SA, Nelson EW, Renlund DG, Karwande SV, Burton NA, Sullivan JJ, Jones KW, Gay WA Jr. Major Abdominal complications following cardiac transplantation. Archives of Surgery 124:889-894, 1989

30. Wittwer CT, Knape WA, Bristow MR, Gilbert EM, Renlund DG, O'Connell JB, DeWitt CW. Quantitative flow cytometric plasma OKT3 assay: Potential application in cardiac transplantation. Transplantation 48:533-535, 1989

31. Karwande SV, Hopfenbeck JA, Renlund DG, Burton NA, Gay WA Jr. An avoidable pitfall in donor selection for cardiac transplantation. J Heart Transplant 8:422-424, 1989

32. Hammond EH, Yowell RL, Nunoda S, Menlove RL, Renlund DG, Bristow MR, Gay WA, Jones KW, O'Connell JB. Vascular (humoral) rejection in cardiac transplantation: Pathologic observations and clinical implications. J Heart Transplant 8:430-443, 1989

33. Stern MD, Weisman HF, Renlund DG, Gerstenblith G, Hano O, Blank PS, Lakatta EG. Laser backscatter studies of intracellular Ca 2+ oscillations in isolated hearts. Am J Physiol 257 (Heart Circ Physiol 26):H665-H673, 1989

34. O'Connell JB, Renlund DG, Bristow MR. Murine monoclonal CD-3 antibody (OKT3) in cardiac transplantation: Three-year experience. Transplantation Proceedings 21 (Supplement 2):31-33, 1989

35. Doty DB, Renlund DG, Caputo GR, Burton NA, Jones KW. Cardiac transplant in situs inversus. J Thoracic and Cardiovascular Surgery 99:493-499, 1990

36. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, Bartholomew M, Mealey PC, Larrabee P, Bristow MR. Chronic B-blocker therapy improves cardiac function in idiopathic dilated cardiomyopathy: A double-blind, randomized study of bucindolol versus placebo. Am J Med 88:223-229, 1990

37. Renlund DG, Gerstenblith G, Fleg JL, Becker LC, Lakatta EG. Interaction between left ventricular end diastolic - end systolic volumes in normal man. Am J Physiol 258:H473-H481, 1990

38. Hammond EH, Watson FS, Bristow MR, O'Connell JB, Gilbert EM, Doty DB, Renlund DG. Fibrinoid necrosis of the temporal artery complicating the treatment of refractory cardiac allograft rejection with murine monoclonal CD-3 antibody (OKT3). J Heart Transplantation 9:236-238, 1990

39. Moore CK, Renlund DG, Rasmussen LG, O'Connell JB. Long-term morbidity of cyclosporine with corticosteroid-free maintenance immunosuppression in cardiac transplantation. Transplant Proceedings 22 (Supplement 1):25-29, 1990

40. Crandall BG, Gilbert EM, Renlund DG, Menlove RL, Herrick CM, Holland CS, Hagan ME, Rasmussen LG, Karwande SV, O'Connell JB, Bristow MR. A randomized trial of the immunosuppressive efficacy of vincristine in cardiac transplantation. Transplantation 50:34-38, 1990

41. Ratkovec RM, Wray RB, Renlund DG, O'Connell JB, Bristow MR, Gay WA Jr, Karwande SV, Doty DB, Millar RC, Menlove RL, Burke JL, Lappe DL, Tsagaris TJ, Sutton RB, Jones KW. Influence of corticosteroid-free maintenance immunosuppression on allograft coronary artery disease following cardiac transplantation. J Thoracic and Cardiovascular Surgery 100:6-12, 1990

42. O'Connell JB, Bristow MR, Rasmussen LG, Ratkovec RM, Gay WA Jr, Jones KW, Renlund DG. Cardiac allograft function with corticosteroid-free maintenance immunosuppression. Circulation 82(Supplement IV):IV-318-IV-321, 1990

43. Hammond EH, Wittwer CT, Greenwood J, Knape WA, Yowell RL, Menlove RL, Craven C, Renlund DG, Bristow MR, DeWitt CW, O'Connell JB. Relationship of OKT3 sensitization and vascular rejection in cardiac transplant patients receiving OKT3 rejection prophylaxis. Transplantation 50:776-782, 1990

44. Olsen SL, O'Connell JB, Bristow MR, Renlund DG. Methotrexate as an adjunct in the treatment of persistent mild cardiac allograft rejection. Transplantation 50:773-775, 1990

45. O'Connell JB, Bristow MR, Hammond EH, Menlove RL, Ensley RD, Ratkovec RM, Renlund DG. Antimurine antibody to OKT3 in cardiac transplantation: Implications for prophylaxis and retreatment for rejection. Transplantation Proceedings 23:1157-1159, 1991

46. Ensley RD, Hammond EH, Renlund DG, Yowell RL, Bristow MR, DeWitt CW, Menlove RL, Ratkovec RM, O'Connell JB. Clinical manifestations of vascular rejection in cardiac transplantation. Transplantation Proceedings 23:1130-1132, 1991

47. Moore CK, O'Connell JB, Renlund DG, Bristow MR, Hammond EH. Cardiac allograft cellular rejection during OKT3 prophylaxis in the absence of sensitization. Transplantation Proceedings 23:1055-1058, 1991

48. O'Connell JB, Renlund DG, Bristow MR, Hammond EH. Detection of allograft endothelial cells of recipient origin following ABO compatible, nonidentical cardiac transplantation. Transplantation 51:438-442, 1991

49. O'Connell JB, Renlund DG, Hammond EH, Wittwer CT, Yowell RL, Jones KW, Gay WA Jr, Menlove RL, Bristow MR. Sensitization to murine monoclonal CD-3 antibody (OKT3) in cardiac transplantation: Correlation with early allograft loss. J Heart Transplant 10:217-222, 1991

50. Hammond EH, Ensley RD, Yowell RL, Craven CM, Bristow MR, Renlund DG, O'Connell JB. Vascular rejection of human cardiac allografts and the role of humoral immunity in chronic allograft rejection. Transplantation Proceedings 23(Supplement 2):26-30, 1991

51. Anderson JL, Gilbert EM, O'Connell JB, Renlund D, Yanowitz F, Murray M, Roskelley M, Mealey P, Volkman K, Deitchman D, Bristow M. Long-term (2 year) beneficial effects of beta-blockade with bucindolol in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 17:1373-1381, 1991

52. O'Connell JB, Gilbert EM, Renlund DG, Bristow MR. Enoximone as a bridge to cardiac transplantation: The Utah experience. J Heart Lung Transplant 10:477-481, 1991

53. Lee HR, Hershberger RE, Port JD, Rasmussen R, Renlund DG, O'Connell JB, Gilbert EM, Mealey PC, Volkman K, Menlove R, Bristow MR. Low-dose enoximone in subjects awaiting cardiac transplantation. J Thorac Cardiovasc Surg 102:246-58, 1991

54. Bristow MR, Anderson FL, Port JD, Skerl L, Hershberger RE, Larrabee P, O'Connell JB, Renlund DG, Volkman K, Murray J, Feldman AM. Differences in ß-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation 84:1024-1039, 1991

55. Richenbacher WE, Karwande SV, Renlund DG, Bristow MR, O'Connell JB, Gay WA Jr. Cardiac transplantation in patients with a single ventricle and transposition of the great vessels. Annals of Thoracic Surgery 52:871-873, 1991

56. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG, Menlove R, Bristow MR. ß-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 84:2426-2441, 1991

57. Marks JD, Karwande SV, Richenbacher WE, Jones KW, Doty DB, Millar RC, O'Connell JB, Renlund DG, Bristow MR, Pantalos GM, Gay WA Jr. Perioperative mechanical circulatory support for transplantation. J Heart Lung Transplant 11:117-1128, 1992

58. Price GD, Olsen SL, Taylor DO, O'Connell JB, Bristow MR, Renlund DG. Corticosteroid-free maintenance immunosuppression following cardiac transplantation: Feasibility and beneficial effects. J Heart Lung Transplant 11 (Supplement):403-414, 1992

59. Merigan TC, Renlund DG, Keay S, Bristow MR, Starnes V, O'Connell JB, Resta S, Dunn D, Gamberg P, Ratkovec RM, Richenbacher WE, Millar RC, DuMond C, DeArmond B, Sullivan V, Cheney T, Buhles W, Stinson EB. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 326:1182-1186, 1992

60. Hammond EH, Yowell RL, Price GD, Menlove RL, Olsen SL, O'Connell JB, Bristow MR, Doty DB, Millar RC, Karwande SV, Jones KW, Gay WA Jr, Renlund DG. Vascular rejection and its relationship to allograft coronary artery disease. J Heart Lung Transplant 11:S111-S119, 1992

61. Ensley RD, Hunt S, Taylor DO, Renlund DG, Menlove RL, Karwande SV, O'Connell JB, Barr ML, Michler RE, Copeland JG, Miller LW, the Registry of the International Society for Heart and Lung Transplantation, and contributing investigators. Predictors of survival following repeat cardiac transplantation. J Heart Lung Transplant 11:S142-S158, 1992

62. Ratkovec R, Hammond EH, O'Connell JB, Bristow MR, DeWitt C, Richenbacher W, Millar R, Renlund DG. Outcome of cardiac transplant recipients with a positive donor specific cross-match: Preliminary results with plasmapheresis. Transplantation 54:651-655, 1992

63. Karwande SV, Ensley RD, Renlund DG, Gay WA Jr, Richenbacher WE, Doty DB, Hammond ME, Marks JD, the Registry for the International Society for Heart and Lung Transplantation. Cardiac retransplantation: A viable option? Ann Thorac Surg 54:840-845, 1992

64. Karwande SV, Renlund DG, Olsen SL, Gay WA Jr, Richenbacher WE, Hawkins JA, Millar RC, Marks JD. Mediastinitis in heart transplantation. Ann Thorac Surg 54:1039-1045, 1992

65. Ratkovec RM, O'Connell JB, Bristow MR, Jones KW, Gay WA Jr, Rasmussen LG, Renlund DG. Post-transplant lymphoproliferative disease in cardiac transplant patients receiving OKT3 therapy. Clinical Transplantation 6(2):260-264, 1992

66. Olsen SL, Wagoner LE, Hammond EH, Taylor DO, Yowell RL, Ensley RD, Bristow MR, O'Connell JB, Renlund DG. Vascular rejection in heart transplantation: Clinical correlation, treatment options, and future considerations. J Heart Lung Transplant 12:S135-S142, 1993

67. Hammond EH, Yowell RL, Greenwood J, Hartung L, Renlund DG, Wittwer C. Prevention of adverse clinical outcome by monitoring of cardiac transplant patients for murine monoclonal CD3 antibody (OKT3) sensitization. Transplantation 55:1061-1063, 1993

68. Shaddy RE, Bullock EA, Morwessel NJ, Hannon DW, Renlund DG, Karwande SV, McGough EC, Hawkins JA. Murine monoclonal CD-3 antibody (OKT3)-based early rejection prophylaxis in pediatric heart transplantation. J Heart Lung Transplant 12:434-439, 1993

69. Gilbert EM, Sandoval A, Larrabee P, Renlund DG, O'Connell JB, Bristow MR. Lisinopril lowers cardiac adrenergic drive and increases ß-receptor density in the failing human heart. Circulation 88:472-480, 1993

70. Ensley RD, Bristow MR, Olsen SL, Taylor DO, Hammond EH, O'Connell JB, Dunn D, Osburn L, Jones KW, Kauffman RS, Gay WA Jr, Renlund DG. Use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 56:75-82, 1993

71. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, and White BG for the OPC-8212 Investigators and coordinators. Results of a multi-center study of OPC-8212 in chronic congestive heart failure. N Engl J Med 329:149-155, 1993

72. Olsen SL, Renlund DG, O'Connell JB, Taylor DO, Lassetter JE, Eastburn TE, Hammond EH, Bristow MR. Prevention of Pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole. Transplantation 56:359-362, 1993

73. Scott JR, Wagoner LE, Olsen SL, Taylor DO, Renlund DG. Pregnancy in heart transplant recipients: Management and outcomes. Obstet Gynecol 82:324-327, 1993

74. DeBruyne LA, Ensley RD, Olsen SL, Taylor DO, Carpenter BM, Holland C, Swanson S, Jones KW, Karwande SV, Renlund DG, Bishop DK. Increased frequency of donor alloantigen-reactive helper T lymphocytes is associated with human cardiac allograft rejection. Transplantation 56:722-727, 1993

75. Nunoda S, Shaddy RE, Bullock EA, Renlund DG, Hammond EH, Yowell RL, Misawa T, Umetani K, Satoh H. The first pediatric Japanese case to undergo heart transplantation in the UTAH Cardiac Transplant Program in the United States. Japanese Circulation Journal 57:873-882, 1993

76. Farrukh HM, White M, Port JD, Handwerger D, Larrabee P, Klein J, Roden RA, Skerl L, Renlund DG, Feldman AM, Bristow MR. Up-regulation of beta-2-adrenergic receptors in previously transplanted, denervated non-failing human hearts. J Am Coll Cardiol 22:1902-1908, 1993

77. Wagoner LE, Olsen SL, Bristow MR, O'Connell JB, Taylor DO, Lappe DL, Renlund DG. Cyclophosphamide as an alternative to azathioprine in cardiac transplant recipients with suspected azathioprine-induced hepatotoxicity. Transplantation 56:1415-1418, 1993

78. Wagoner LE, Taylor DO, Olsen SL, Price GD Sr, Rasmussen LG, Larsen CB, Scott JR, Renlund DG. Immunosuppressive therapy, management, and outcome of cardiac transplant recipients during pregnancy. J Heart Lung Transplant 12:993-1000, 1993

79. Wagoner LE, Taylor DO, Price GD, Hagan ME, Holland C, Olsen SL, Renlund DG. Paternity by cardiac transplant recipients. Transplantation 57:1337-1340, 1994

80. Taylor DO, Ensley RD, Olsen SL, Dunn D, Renlund DG. Mycophenolate mofetil (RS-61443): Preclinical, clinical and three-year experience in cardiac transplantation. J Heart Lung Transplant 13:571-582, 1994

81. Baay P, Karwande SV, Kushner JP, Olsen S, Renlund DG. Successful treatment of a cardiac angiosarcoma with combined modality therapy. J Heart Lung Transplant 13:923-925, 1994

82. Taylor DO, Bristow MR, O'Connell JB, Ensley RD, Olsen SL, Hammond EH, Wagoner LE, Renlund DG. A prospective, randomized comparison of cyclophosphamide and azathioprine for early rejection prophylaxis after cardiac transplantation: Decreased sensitization to OKT3. Transplantation 58:645-649, 1994

83. Fleg JL, Schulman S, O'Connor F, Becker LC, Gerstenblith G, Clulow JF, Renlund DG, Lakatta EG. Effects of acute ß-adrenergic receptor blockade on age-associated changes in cardiovascular performance during dynamic exercise. Circulation 90:2333-2341, 1994

84. Shaddy RE, Bullock EA, Tani LY, Orsmond GS, Olsen SL, Taylor DO, McGough EC, Hawkins JA, Renlund DG. Methotrexate therapy in pediatric heart transplantation as treatment of recurrent mild to moderate acute cellular rejection. J Heart Lung Transplant 13:1009-1013, 1994

85. Shaddy RE, Olsen SL, Bristow MR, Taylor DO, Bullock EA, Tani LY, Renlund DG. Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. Am Heart J 129:197-199, 1995

86. Gill EA, Borrego C, Bray BE, Renlund DG, Hammond EH, Gilbert EM. Left ventricular mass increases during cardiac allograft vascular rejection. J Am Coll Cardiol 25:922-926, 1995

87. DeBruyne LA, Renlund DG, Bishop DK. Evidence that human cardiac allograft acceptance is associated with a decrease in donor-reactive helper T-Lymphocytes. Transplantation 59:778-783, 1995

88. Stahl RD, Karwande SV, Olsen SL, Taylor DO, Hawkins JA, Renlund DG. Tricuspid valve dysfunction in the transplanted heart. Ann Thorac Surg 59:477-480, 1995

89. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study. J Am Coll Cardiol 25:1225-1231, 1995

90. Bull DA, Stahl RD, McMahan DL, Jones KW, Hawkins JA, Renlund DG, Taylor DO, Karwande SV. The high-risk heart donor: Potential pitfalls. J Heart Lung Transplant 14:424-428, 1995

91. Taylor DO, Olsen SL, Ensley RD, Renlund DG. Methotrexate for rejection prophylaxis after cardiac transplantation. J Heart Lung Transplant 14:950-940, 1995

92. White, M, Yanowitz F, Gilbert EM, Larrabee P, O'Connell JB, Anderson JL, Renlund DG, Mealey P, Abraham WT, Bristow MR. Role of beta-adrenergic receptor down-regulation in the peak exercise response in patients with heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol 76:1271-1276, 1995

93. Peeters GA, Sanguinetti MC, Eki Y, Konarzewska, Renlund DG, Karwande SV, Barry WH. A method for isolation of human ventricular myocytes from single endocardial and epicardial biopsies. Am J Physiol (Heart and Circulatory Physiology) 268:H1757-64;April 1995

94. Renlund DG, Taylor DO, Ensley RD, O'Connell JB, Gilbert EM, Bristow MR, Ma H, Yanowitz FG. Exercise capacity after cardiac transplantation: Influence of donor and recipient characteristics. J Heart Lung Transplant 15:16-24, 1996

95. Bull DA, Karwande SV, Hawkins JA, Neumayer LA, Taylor DO, Jones KW, Renlund DG, Putnam CW. Long-term results of cardiac transplantation in patients older than sixty years. J Thoracic and Cardiovascular Surgery 111:423-428, 1996

96. Renlund DG , Gopinathan SK, Kfoury AG, Taylor DO. Mycophenolate mofetil (MMF) in heart transplantation: Rejection prevention and treatment. Clinical Transplantation 10:136-139, 1996

97. Ma H, Hammond EH, Taylor DO, Yowell RL, Bristow MR, O’Connell JB, Renlund DG. The repetitive histologic pattern of vascular cardiac allograft rejection: Increased incidence associated with longer exposure to prophylactic murine monoclonal anti-CD3 antibody (OKT3). Transplantation 62:205-210, 1996

98. Taylor DO, Bristow MR, O’Connell JB, Price GD, Hammond EH, Doty DB, Karwande SV, Gay WA Jr, Jones KW, Lappe D, Renlund DG. Improved long-term survival after heart transplantation predicted by successful early withdrawal from maintenance corticosteroid therapy. J Heart Lung Transplant 15:1039-1046, 1996

99. Wagoner LE, Taylor DO, Olsen SL, Bristow MR, O'Connell JB, Hammond EH, Lappe DL, Renlund DG. Cyclophosphamide in cardiac transplant recipients with frequent rejection: A six-year retrospective review. Clinical Transplantation 1996;10:437-443

100. Rodriguez-Larrain JM, Ziebert JJ, Kfoury AG, Kuwada S, Taylor DO, Renlund DG. Incidence of adenomatous colorectal polyps in cardiac transplant recipients. Transplantation 1997;64:528-530

101. Kfoury AG, Smith JC, Farhoud HH, Terreros DA, Stringham JC, Taylor DO, Renlund DG. Adjuvant intrapleural amphotericin B therapy for pulmonary mucormycosis in a cardiac allograft recipient. Clinical Transplantation 1997;11:608-612

102. Kobashigawa J, Miller L, Renlund DG Mentzer R, Alderman E, Bourge R, Costanzo M, Eisen H, Dureau G, Hershberger R, Hummel M, Ipe D, Johnson J, Keogh A, Mamelok R, Mancini D, Smart F, Valantine H. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998;66:507-515

103. Stringham JC, Bull DA, Fuller TC, Kfoury AG, Taylor DO, Renlund DG, Karwande SV. Avoidance of cellular blood product transfusion in LVAD recipients does not prevent HLA allosensitization. J Heart Lung Transplant 1999;18:160-165

104. Valantine HA, Gao S-Z, Menon SG, Renlund DG, Hunt SA, Oyer P, Stinson EB, Brown BW Jr, Merigan T, Schroeder JS. Impact of prophylactic immediate post-transplant ganciclovir on development of transplant atherosclerosis: A post-hoc analysis of a randomized placebo-controlled trial. Circulation 1999;100:61-66

105. Taylor DO, Barr ML, Radovancevic B, Renlund DG, Mentzer RM Jr, Smart FW, Tolman DE, Frazier OH, Young JB, Van Veldhuisen P. A randomized, multi-center comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: Decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999;18:336-345

106. Taylor DO, Sharma RC, Kfoury AG, Renlund DG. Increased incidence of allograft rejection in stable heart transplant recipients after late conversion from myocophenolate mofetil to azathioprine. Clinical Transplantation 1999;13:296-299

107. Eisen HJ, Hobbs RE, Davis SF, Laufer G, Mancini DM, Renlund DG, Valantine H, Ventura H, Antoine M, Bourge RC, Canver CC, Carrier M, Costanzo M-R, Copeland J, Dureau G, Frazier OH, Gandjbakhch I, Hauptman PI, Kells C, Masters R, Michaud JL, Paradis I, Smith A, Vanhaecke J, Feutren G, Turkin D, Mellein B, Mueller E. Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: A randomized, multi-center, double-blind comparison with the oil based formulations of cyclosporine - Results at six months after transplantation. Transplantation 1999;68:663-671

108. Taylor DO, Yowell RL, Kfoury AG, Hammond EH, Renlund DG. Allograft coronary artery disease: Clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. J Heart Lung Transplant 2000;19:518-521

109. Taylor DO, Farhoud HH, Kfoury AG, Pham SM, Pigula FA, Kormos RL, Renlund DG. Cardiac transplantation in survivors of lymphoma: A multi-institutional survey. Transplantation 2000;69:2112-2115

110. Eisen HJ, Hobbs RE, Davis SF, Carrier M, Mancini DM, Smith A, Valantine H, Ventura H, Mehra M, Vachiery J-L, Bourge RC, Canver CC, Laufer G, Costanzo M-R, Copeland J, Dureau G, Frazier OH, Dorent R, Hauptman PI, Kells C, Masters R, Michaud J-L, Paradis I, Renlund DG, Vanhaecke J, Mellein B, Mueller EA. Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: A randomized multi-center, double-blind comparison with the oil based formulation of cyclosporine - Results at twenty-four months after transplantation. Transplantation 2001;71:70-78

111. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-1667

112. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Bembitsky W, Long JW, Ascheim DD, Tierney AR, Levitan RG, Watson JT, Meier P for the REMATCH Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001;345:1435-1443

113. Doing AH, Renlund DG, Smith RA. Becker muscular dystrophy-related cardiomyopathy: A favorable response to medical therapy. J Heart Lung Transplant 2002;21:496-498

114. Aranda JM Jr, Krause-Steinrauf HJ, Greenberg BH, Heng MK, Kosolcharoen PK, Renlund DG, Thaneemit-chen S, White M, Cintron GB. Comparison of the beta-blocker bucindolol in younger versus older patients with heart failure. Am J Cardiol 2002;89:1322-1326

115. Peterson MC, Whetten DK, Renlund DG, Coletti A. Sensitivity of rhythm disturbance detection by community hospital telemetry. Ann Non-invasive Electrocardiol 2002;7:219-221

116. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, O’Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M, for the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure. JAMA 2002;287:1541-1547

117. Eisen, HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, Sorensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P, for the RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349:847-858

118. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, for the ATTACH Investigators. Randomized, double blind, placebo-controlled, pilot train of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure. Results of the anti-TNF therapy against congestive heart failure (ATTACH) Trail. Circulation 2003;107;3133-3140

119. Anderson JL, Krause-Steinrauf H, Goldman S, Clemson BS, Domanski MJ, Hager WD, Murray DR, Mann DL, Massie BM, McNamara DM, Oren R, Rogers WJ, for the B-Blocker evaluation of survival trail (BEST) investigators. J Cardiac Failure 2003; 9:266-277.

120. Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, Canby RC, Schroeder JS, Liem LB, Hall S, Wheelan K, for The Multicenter InSync ICD Randomized Clinical Evaluation (MIRCLE ICD) Trial Investigators. Combined Cardiac Resynchronization and Implantable Cardioversion Defibrillation in Advanced Chronic Heart Failure. JAMA, May 28, 2003 – Vol. 289, No.20.

121. Goodlin SJ, Hauptman PJ, Arnold R, Grady K, Hershberger RE, Kutner J, Masoudi F, Spertus J, Dracup K, Cleary JF, Medak R, Crispell K, Pina I, Stuart B, Thitney C, Rector T, Teno J, Renlund DG. Consenus Statement: Palliative and Supportive Care in Advanced Heart Failure. J of Cardio Failure 2004;10:200-209

122. Horton S, Khodaverdian R, Powers A, Revenaugh J, Horne B, Long J, Renlund DG, Moore, SA, Rasmusson B., Left Ventricular Assist Device Malfunction: A Systematic Approach to Diagnosis. Journal of the American College of Cardiology 2004;43.9.1574-1583

123. Stevenson LW, Miller LW, Desvigne-Nickens P, Ascheim DD, Parides MK, Renlund DG, Oren RM, Krueger SK, Costanzo MR, Wann LS, Levitan RG, Mancini D, for the REMATCH Investigators. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: A subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). J Am Coll Cardiol 2004;110:975-981

124. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, DeMarco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries D, Feldman AM for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-2150

125. Yazaki Y, Muhlestein JB, Carlquist JF, Bair TL, Horne BD, Renlund DG, Anderson JL. A common variant of the AMPD1 gene predicts improved survival in patients with ischemic left ventricular dysfunction. J Cardiac Failure 2004;10:316-320

126. Horne BD, Muhlestein JB, Lappe’ DL, Renlund DG, Bair TL, Bunch TJ, Anderson JL, Less affluent area of residence and lesser-insured status predict an increase risk of death or myocardial infarction after angiographic diagnosis of coronary disease. Ann Epidemiol 2004;14:143-150

127. Lappe’ JM, Muhlestein JB, Lappe’ DL, Badger RS, Bair TL, Brockman R, French TK, Hofmann LC, Horne BD, Kralick-Goldberg S, Nicponski N, Orton JA, Pearson RR, Renlund DG, Rimmasch H, Roberts C, Anderson JL. Improvements in 1-year cardiovascular clinical outcomes associated with a hospital-based discharge medication program. Ann Intern Med 2004;141:446-453

128. Alharehti R, Shaddy RE, Doty DB, Moore SA, Hammond MEH, Dabbas B, Fuller TC, Renlund DG, Early failure of a tricuspid valve replacement with a mitral valve homograft in a heart transplant recipient. J Heart Lung Transplant 2004;23:1460-1462

129. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH, for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-237

130. Horne BD, Anderson JL, Carlquist JF, Muhlestein JB, Renlund DG, Bair TL, Pearson RR, Camp NJ. Generating genetic risk scores from intermediate phenotypes for use in association studies of clinically significant endpoints. Annals of Human Genetics 2005;69:176-186

131. Horne BD, Anderson JL, John JM, Weaver A, Bair TL, Jensen KR, Renlund DG, Muhlestein JB. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol 2005;45:1638-1643

132. Eisen HJ, Kobashigawa J, Keogh A, Bourge R, Renlund D, Mentzer R, Alderman E, Valantine H, Dureau G, Mancini D, Mamelok R, Gordon R, Wang W, Mehra M, Constanzo MR, Hummel M, Johnson J, Mycophenolate Mofetil Cardiac Study Investigators. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005;24:517-525

133. Hershberger RE, Starling RC, Eisen HJ, Berg C-H, Kormos RL, Love RB, Van Bakel A, Gordon RD, Popat R, Cockey L, Mamelok RD. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005;352:2705-2713

134. Muhlestein JB, Anderson JL, Cui CZ, Lan YP, Bair TL, Bunch TJ, Pearson RR, Sorensen SG, Renlund DG, Zhang L, Horne BD, Vincent GM. Improved long-term survival associated with stent deployment during percutaneous coronary interventions: Results from a registry of 3,399 patients. American Heart Journal 2005;150:182-188

135. Ronnow BS, Reyna SP, Muhlestein JB, Horne BD, Maycock CAA, Bair TL, Carlquist JF, Kfoury AG, Anderson JL, Renlund DG. C-Reactive protein predicts death in patients with non-ischemic cardiomyopathy. Cardiology 2005;104:196-201

136. Anderson JL, Muhlestein JB, Bair TL, Morris S, Weaver AN, Lappe DL, Renlund DG, Pearson RR, Jensen KR, Borne BD. Do statins increase the risk of ideiopathic polyneuropathy? Am J Cardiol 2005;95:1097-1099

137. Jones H, Horne BD, Renlund DG, Doty DB, Lappe’ DL, Muhlestein JB, Anderson JL, Jones K, Bair T. Early postoperative use of unfractionated heparin or enoxaparin is associated with increased surgical re-exploration for bleeding. Ann Thorac Surg 2005;80:518-522

138. Bunch TJ, Muhlestein JB, Bair TL, Renlund DG, Lappe DL, Jensen KR, Horne BD, Carter MA, Anderson JL. Effect of beta-blocker therapy on mortality rates and future myocardial infarction rates in patients with coronary artery disease but no history of myocardial infarction or congestive heart failure. Am Heart J 2005;95:827-831

139. Alharethi R, Bader F, Doty DB, Hagan ME, Kfoury AG, Karwande S, Gilbert EM, Thomas H, Renlund DG. Tricuspid valve replacement after cardiac transplantation. (J Heart Lung Transplant (IN PRESS)

140. Dracos SG, Long JW, Stringham JC, Kfoury AG, Gilbert EM, Moore SA, Campbell BA, Nelson KE, Renlund DG. Effect of mechanical circulatory support on outcomes after heart transplantation. J Heart Lung Transplant (IN PRESS)

141. Hammond EH, Stehlik J, Snow G, Renlund DG, Seaman J, Dabbas B, Gilbert EM, Srtingham JC, Long JW, Kfoury AG. Utility of Histologic Parameters in Screening for Antibody-mediated Rejection of the Cardiac Allograft: A Study of 3170 Biopsies. J Heart Lung Transplant (In Press)

142. Bader F, Renlund DG, Kfoury AG, Percutaneous Interventions with Stents in Cardiac Transplant Recipients. J Heart Lung Transplant (In Press)

143. Long JW, Rasmusson BY, Cowley CG, Nelson KE, Kfoury AG, Clayson SE, Reid BB, Blank DU, Renlund DG. Improving Outcomes with Long-term Destination Therapy Using Left Ventricular Assist Devices. J Thorac Cardiovasc Surg (In Press)

144. Vigano M, Eisen H, Benza R, Boissonat P, Haverich A, Hill J, Laufer G, Love R, Parameshwar J, Pulpon LA, Renlund D, Abeywickrama K, Cretin N, Tuzcu M for the RAD B253 Study Group. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplant recipients: A 24 month analysis. (SUBMITTED)